| 22.98 -1.3 (-5.35%) | 12-05 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 29.75 |
1-year : | 35.04 |
| Resists | First : | 25.47 |
Second : | 30 |
| Pivot price | 25.61 |
|||
| Supports | First : | 18.14 |
Second : | 15.1 |
| MAs | MA(5) : | 24.88 |
MA(20) : | 25.16 |
| MA(100) : | 19.96  |
MA(250) : | 0 | |
| MACD | MACD : | 1.1 |
Signal : | 1.6 |
| %K %D | K(14,3) : | 16.8 |
D(3) : | 26.9 |
| RSI | RSI(14): 45.8 |
|||
| 52-week | High : | 30 | Low : | 3.42 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ URGN ] has closed above bottom band by 17.8%. Bollinger Bands are 73.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 19 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 24.81 - 25.05 | 25.05 - 25.19 |
| Low: | 22.03 - 22.33 | 22.33 - 22.5 |
| Close: | 22.64 - 23.12 | 23.12 - 23.41 |
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Fri, 05 Dec 2025
Bronstein, Gewirtz & Grossman, LLC Is Investigating UroGen Pharma - The National Law Review
Fri, 05 Dec 2025
UroGen Pharma (URGN) Issues Stock Units to New Employees - GuruFocus
Fri, 05 Dec 2025
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fri, 05 Dec 2025
UroGen Pharma Ltd. (NASDAQ:URGN) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected - simplywall.st
Thu, 04 Dec 2025
Panagora Asset Management Inc. Acquires 168,908 Shares of Urogen Pharma $URGN - MarketBeat
Wed, 03 Dec 2025
Urogen Pharma (NASDAQ:URGN) Trading Down 6.1% - What's Next? - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 47 (M) |
| Shares Float | 37 (M) |
| Held by Insiders | 6.7 (%) |
| Held by Institutions | 101 (%) |
| Shares Short | 8,980 (K) |
| Shares Short P.Month | 11,150 (K) |
| EPS | -3.48 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.48 |
| Profit Margin | -170.6 % |
| Operating Margin | -99.7 % |
| Return on Assets (ttm) | -34 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 9 % |
| Gross Profit (p.s.) | 1.81 |
| Sales Per Share | 2.06 |
| EBITDA (p.s.) | -2.81 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -138 (M) |
| Levered Free Cash Flow | -66 (M) |
| PE Ratio | -6.63 |
| PEG Ratio | 0 |
| Price to Book value | -9.31 |
| Price to Sales | 11.14 |
| Price to Cash Flow | -7.81 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|